Umbilical cord blood (UCB) transplants have been shown to produce comparable results to those obtained from mismatched unrelated bone marrow transplants for adult patients with hematologic malignancies. 1, 2 Despite the less stringent HLA-matching criteria used for UCB transplants, the incidence of GVHD is acceptable 1,2 without compromising the antitumor effects. 3, 4 However, most of the published studies on UCB transplants have involved primarily younger adults, with a median age of less than 40 years. Majhail et al., 5 recently addressed the role of unrelated UCB transplants for older patients and reported that the results of UCB transplants carried out in 43 adult patients older than 55 years were comparable to those obtained from 47 matched related donor transplants. The 3-year probability of progression-free survival was 34% in UCB transplants compared with 30% in matched related donor transplants and suggested that HLA-mismatched UCB could be an alternative graft source for older patients who need a transplant but do not have a matched related donor.
We have carried out an analysis of the results of older patients who have undergone reduced-intensity mismatched UCB transplant in our program. Nine older patients, median age 60 years (range 48-77 years) have received mismatched UCB; 78% of these patients received two UCB units to optimize the cell dose. Two patients received one HLA-mismatched, four patients two HLAmismatched and three patients three HLA-mismatched grafts. Clinical characteristics of these patients and the infused UCB units are shown in Table 1 . There were six male patients and three female patients. Their median weight was 72 kg (range 60-98 kg). Eight patients had AML, two with primary refractory AML, and one patient had advanced refractory CLL. Four patients had hematopoietic cell transplantation comorbidity scores of X2 before transplant. GVHD prophylaxis in all patients consisted of oral cyclosporine starting day À2, and methylprednisone starting day þ 7 at 2 mg/kg/day until day þ 28 when it was reduced by half every week. The methylprednisone was discontinued on day þ 56 in the absence of significant GVHD.
Neutrophil engraftment was documented in seven patients. Two patients died before engraftment could be evaluated. The median time to neutrophil count 40.5 Â 10 6 /l was 24 days (range 18-39 days). All engraftment was confirmed by molecular studies. Only one of the two donor units was documented to engraft in all seven patients who received double UCB transplants. Five patients became independent of platelet transfusion and five patients of red blood cell transfusion. In one patient in whom the follow-up period was still short, the patient remained blood and platelet transfusion-dependent on day þ 52. Acute GVHD occurred in all seven evaluated patients who were engrafted. Despite the high degrees of antigen mismatching and age of this group of patients, grade I-II acute GVHD occurred in six patients and grade III-IV only in one patient, who died of fatal GVHD, involving the intestine. GVHD in all patients was treated with high-dose methylprednisone with, or without mycophenolate. None of the three evaluable surviving patients developed significant chronic GVHD; one patient developed limited chronic GVHD involving his periorbital region.
As four of the nine patients had high hematopoietic cell transplantation comorbidity scores before transplant, early TRM was high: at 28 days it was 22% and at 100 days 62.5%. Most deaths occurred due to toxicities and infections. All four patients 465 years died. The median survival for the group is 55 days (range 16-1122 days). As of May 30, 2008, four patients are alive and disease-free, 52 þ days, 616 þ days, 797 þ days and 1122 þ days posttransplant. The actuarial 3-year survival rate for the group is 40%. Outcomes of all nine patients are summarized in Table 1 .
In conclusion, our results show that some older patients needing a hematopoietic stem cell transplant may benefit from a mismatched UCB transplant if their underlying disease did not benefit from autologous transplantation and if they did not have a matched related donor. Obviously, longer follow-up is needed to better determine the long-term effect of this approach in older patients. However, further optimization of the conditioning regimen and careful selection of patients based on the hematopoietic cell transplantation comorbidity score are needed for patients older than 65 years to reduce early TRM. 
